CHRS vs CNC · rev $26.6M vs P/E 8.4, rev $103.52B
Coherus BioSciences Inc (CHRS) versus Centene Corp (CNC) — a side-by-side from cached financials, not a winner call.
Coherus BioSciences Inc (CHRS) is a biotechnology company listed on US.
Centene Corp (CNC) is a healthcare plans company listed on US.
Latest reported CHRS revenue for 2026-06-30 was $26.6M. Net income was -$59.0M. CHRS currently screens at market cap $223.7M.
Latest reported CNC revenue for 2026-06-30 was $103.52B. Net income was $2.63B. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
CHRS currently screens at market cap $223.7M. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
Not investment advice. Open the CHRS and CNC stock pages for the full models.
Not investment advice.